Macro Insights - The macro policy for the second half of the year may involve non-traditional measures, with a focus on price stability and the marginal improvement of asset prices, particularly in equity products [2][32] - The "anti-involution" policy is expected to drive companies to reduce capital expenditures and clear excess capacity, leading to improved economic supply-demand relationships and enhanced corporate profitability [3][44] Strategy Insights - The "anti-involution" trend is identified as a key driver for a bullish market, with high-quality stocks likely to play a crucial role in pushing indices higher [3][44] - AI is recognized as a core driver of the current technological revolution, creating investment opportunities across multiple industries in the A-share market [3][44] - Key sectors to watch in July include solid-state batteries, domestic computing power, non-bank financials, defense and military, and innovative pharmaceuticals, all showing signs of marginal improvement [3][44] Market Performance - The Shanghai Composite Index closed at 3510.18, reflecting a weekly increase of 1.09% [5][7] - The Shenzhen Component Index closed at 10696.10, with a weekly increase of 1.78% [8] Economic Indicators - The manufacturing PMI rose to 49.7% in June, indicating a slight recovery, while the construction PMI significantly improved to 52.8% due to accelerated infrastructure projects [12][13] - Consumer spending showed mixed results, with significant growth in automobile and home appliance sales driven by government subsidies, while other sectors like clothing and cosmetics remained weak [13][14] Industry Trends - The real estate market continues to face challenges, with declining sales and investment, leading to a negative outlook for related sectors [13][14] - The "anti-involution" policy is expected to address price competition and improve product quality, particularly in the durable consumer goods sector [30][44]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 和鉑醫藥控股有限公司 呈交日期： 2025年7月11日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02142 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | 事件 | 已發行股份（不包括庫存股份）數 目 | ...

Core Insights - The Chinese government emphasizes the importance of strengthening pharmaceutical innovation and research to support public health and the development of innovative drugs and medical devices [1] - The trend of Chinese innovative drugs going global is gaining momentum, with significant increases in business development (BD) transactions and funding [2][3] - The pharmaceutical sector is expected to recover in 2025, driven by high-value BD transactions and an improving policy environment [3][4] Industry Developments - The Chinese innovative drug market is projected to see a surge in international collaborations, with over 80 BD projects completed by 2025, indicating a growing global competitiveness [2] - In Q1 2025 alone, BD transactions reached 41, with a total value of approximately 369.29 billion USD, nearing the total for the previous year [2] - Major transactions include the licensing of PD-1/VEGF dual antibody SSGJ-707 to Pfizer for 60.5 billion USD and the global rights for Tislelizumab to Vor Bio for up to 42.3 billion USD [2] Company Highlights - Companies like 基石药业-B (02616) showcased innovative products at the AACR annual meeting, highlighting their advancements in clinical research [5] - 和誉-B (02256) received priority review for its CSF-1R inhibitor for treating TGCT, indicating regulatory support for innovative therapies [6] - 和铂医药 (02142) entered a significant strategic partnership with AstraZeneca, securing 1.75 billion USD in upfront payments and potential milestone payments totaling up to 44 billion USD [6] - 信达生物 (01801) aims to achieve 20 billion RMB in product sales by 2027, with multiple catalysts expected in the coming years, including potential drug launches and data readouts [7]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 和鉑醫藥控股有限公司 HBM Holdings Limited （於開曼群島註冊成立的有限公司） （股份代號：02142） 自願公告 有關恩凱賽藥的A+++輪融資 本公告由和鉑醫藥控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）按自 願基準作出，以知會本公司股東（「股東」）及潛在投資者有關本集團的最新業務進 展。 本公司董事會（「董事會」）欣然宣佈，本公司所投資的公司上海恩凱細胞技術有限 公司（「恩凱賽藥」）近日已完成A+++輪融資，本輪融資由多名投資者參與，融資 近人民幣1億元。所得款項將用於推進其核心NK細胞療法產品候選藥物的臨床試 驗，並支持其產品管線的開發。 此次成功融資反映出恩凱賽藥在NK細胞療法開發領域持續取得突破，表明投資人 對其創新免疫治療平台充滿信心，所獲資金將為加速臨床轉化提供重要支撐。 關於恩凱賽藥 恩凱賽藥是一家生物科技公司，專注於NK細胞療法創新技術的研發。2024年， ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 和鉑醫藥控股有限公司 呈交日期： 2025年7月8日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02142 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 ...

Summary of Key Points Core Viewpoint - On July 7, 34 Hong Kong-listed companies conducted share buybacks, totaling 30.99 million shares and an aggregate amount of HKD 921 million [1][2]. Group 1: Buyback Details - Tencent Holdings repurchased 1.002 million shares for HKD 501 million, with a highest price of HKD 502.000 and a lowest price of HKD 494.400, bringing its total buyback amount for the year to HKD 38.542 billion [1][2]. - AIA Group repurchased 5.5 million shares for HKD 377 million, with a highest price of HKD 69.150 and a lowest price of HKD 68.050, totaling HKD 16.352 billion in buybacks for the year [1][2]. - Founder Holdings repurchased 10.386 million shares for HKD 1.174 million, with a highest price of HKD 1.150 and a lowest price of HKD 1.110, accumulating HKD 3.541 million in buybacks for the year [1][2]. Group 2: Buyback Rankings - The highest buyback amount on July 7 was from Tencent Holdings at HKD 501 million, followed by AIA Group at HKD 377 million [1][2]. - In terms of share quantity, Founder Holdings had the most significant buyback with 10.386 million shares, followed by AIA Group with 5.5 million shares and China Electric Power Technology with 2.26 million shares [1][2].

翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 和鉑醫藥控股有限公司 FF305 呈交日期： 2025年7月7日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02142 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | | 已發行股份（不包括庫 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 和鉑醫藥控股有限公司 HBM Holdings Limited （於開曼群島註冊成立的有限公司） （股份代號：02142） 授出購股權 本公告乃根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」） 第17.06A條刊發。 和鉑醫藥控股有限公司（「本公司」，連同其附屬公司統稱為「本集團」）董事會 （「董事會」）謹此宣佈，於2025年6月30日，根據本公司股東（「股東」）於2020年 11月23日採納的購股權計劃（「購股權計劃」），本公司向合資格參與者授出購股權 （「購股權」），惟須待承授人接納後生效。 授出購股權 授出購股權（「授出購股權」）的詳情如下： 授出日期： 2025年6月30日 所授出購股權數目： 3,465,000份 1 承授人數目： 三名本集團非關連僱員（不包括高級管理層）（「購股 權承授人」） 所授出購股權行權價格： 每股本公司股份（「股份」）8.604港元。行權價格為以 ...

Core Viewpoint - The article discusses a patent dispute between two leading Chinese biopharmaceutical companies, Heptares Therapeutics and Baiaosaitu, focusing on their antibody technology platforms, which are crucial for their revenue and cash flow [2][5]. Company Overview - Heptares Therapeutics, known as "China's BD King," provides drug development and antibody technology to global pharmaceutical companies [4]. - Baiaosaitu, referred to as "China's Mouse King," initially focused on providing transgenic mice for drug testing and has developed its own antibody technology platform [4][13]. Patent Dispute Details - The core of the patent dispute involves a technology for producing antibody drugs, which is essential for both companies' operations [5]. - Heptares' technology was acquired from a Dutch company in 2016 and received patent authorization in China in 2022 after a lengthy legal battle [6][18]. - Baiaosaitu's technology was developed internally over ten years, with claims that it could reach Heptares' level in just three months [7]. - Heptares filed a lawsuit against Baiaosaitu in September 2024, alleging patent infringement, while Baiaosaitu countered by challenging the jurisdiction and claiming Heptares' patent is invalid [7][8]. Financial Performance - Heptares has secured significant contracts, including a deal worth up to $620 million, and has generated $185 million in revenue from licensing its technology from 2020 to 2024 [11]. - Baiaosaitu's antibody business revenue reached 318 million yuan in 2024, with a year-on-year growth of over 80% [14]. Technology Comparison - The article highlights the differences in technology between the two companies, with Baiaosaitu's platform utilizing a more comprehensive gene replacement method compared to Heptares' approach [22][25]. - The dispute centers on whether the methods of producing heavy-chain antibodies are equivalent, with differing opinions on the implications of gene usage [25]. Market Impact - The ongoing patent dispute has affected the market valuations of both companies, with Heptares' stock experiencing significant fluctuations in response to developments in the case [23].

Core Viewpoint - A patent dispute between two leading Chinese biopharmaceutical companies, Heptares Therapeutics-B and Baiaosaitu-B, has emerged, impacting their market valuations and highlighting the significance of their antibody technology platforms [2][4]. Company Overview - Heptares Therapeutics, based in Shanghai, is known as the "King of BD" in China, providing drug development and antibody technology to global pharmaceutical companies [2]. - Baiaosaitu, located in Beijing, is referred to as the "Mouse King" and specializes in providing transgenic mice for drug testing [2]. Patent Dispute Details - The core of the dispute revolves around a technology for producing antibody drugs, which is crucial for the revenue and cash flow of both companies [2]. - Heptares acquired its technology from a Dutch company in 2016, receiving patent authorization in 2022 after a lengthy legal battle with the Chinese National Intellectual Property Administration [3][10]. - Baiaosaitu developed its technology internally over a decade, claiming it could reach Heptares' level in just three months [3]. Legal Proceedings - Heptares filed a lawsuit against Baiaosaitu in September 2024, alleging patent infringement, while Baiaosaitu challenged the jurisdiction and sought to invalidate Heptares' patent [3][4]. - In mid-2025, Baiaosaitu's counteractions were unsuccessful, with the Supreme Court affirming the jurisdiction of the Shanghai Intellectual Property Court and the validity of Heptares' patent [4]. Financial Performance - Heptares secured a significant contract worth up to $620 million, with $47 million in upfront payments, and has generated $185 million in revenue from licensing its technology from 2020 to 2024 [5][6]. - Baiaosaitu's antibody business revenue reached 318 million yuan in 2024, marking an over 80% year-on-year growth, with partnerships established with seven of the top ten global pharmaceutical companies [8]. Technology Comparison - The dispute has sparked discussions among investors regarding the superiority of the two companies' platforms, with some favoring Baiaosaitu's technology as more advanced [7][14]. - Baiaosaitu's platform utilizes a method that incorporates over 120 human V genes, while Heptares' platform only integrates nine, leading to claims of a technological edge [13][14]. Market Impact - Following the public disclosure of the patent dispute, Heptares' stock price fell by 15.47% as investors reacted to the perceived advantages of Baiaosaitu's technology [14].